Blueshift Asset Management LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,325 shares of the medical research company's stock, valued at approximately $345,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Viawealth LLC raised its position in shares of Amgen by 0.9% during the fourth quarter. Viawealth LLC now owns 7,594 shares of the medical research company's stock worth $1,979,000 after acquiring an additional 66 shares during the last quarter. iA Global Asset Management Inc. raised its holdings in Amgen by 5.8% during the 4th quarter. iA Global Asset Management Inc. now owns 57,938 shares of the medical research company's stock worth $15,101,000 after purchasing an additional 3,164 shares during the last quarter. Magnetar Financial LLC acquired a new position in Amgen during the 4th quarter valued at about $5,268,000. Teacher Retirement System of Texas boosted its stake in shares of Amgen by 31.3% in the 4th quarter. Teacher Retirement System of Texas now owns 190,666 shares of the medical research company's stock valued at $49,695,000 after purchasing an additional 45,450 shares during the last quarter. Finally, Royal London Asset Management Ltd. lifted its holdings in Amgen by 0.6% in the fourth quarter. Royal London Asset Management Ltd. now owns 230,790 shares of the medical research company's stock valued at $60,153,000 after buying an additional 1,424 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.
Analyst Ratings Changes
A number of analysts have commented on AMGN shares. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. UBS Group reiterated a "hold" rating on shares of Amgen in a report on Wednesday, February 12th. Redburn Partners cut their target price on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft decreased their target price on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Finally, StockNews.com downgraded shares of Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $314.04.
Get Our Latest Analysis on Amgen
Insider Buying and Selling at Amgen
In related news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company's stock, valued at $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 in the last ninety days. 0.69% of the stock is currently owned by corporate insiders.
Amgen Stock Down 0.4 %
NASDAQ AMGN traded down $1.15 during trading hours on Wednesday, hitting $305.71. 2,374,813 shares of the company traded hands, compared to its average volume of 2,548,827. The stock has a market capitalization of $164.23 billion, a price-to-earnings ratio of 40.49, a P/E/G ratio of 2.63 and a beta of 0.53. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The business's 50-day moving average is $298.92 and its 200-day moving average is $298.41. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Sell-side analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.
Amgen Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio is 126.09%.
About Amgen
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
